Board summary
Key figures
27,823
Registered population
61.4% aged 18–64
20.1%
Aged 65+
ICB 19.0% · England 17.9%
5.8%
Ethnic minority (non-White)
2.7% Asian · England 9.6%
22.8%
In IMD quintile 1
ICB 31.9% · England 21.0%
~3,741
Core20 residents (est.)
Resident basis; registered basis ~6,878 · see page 3
5,339
Hypertension register
+5.85% in 3 yrs · England +5.60%
275
SMI register
12.3% of Warrington (LAD)'s
624
COPD register
Reviews -16.04% in 3 yrs
Forecast to 2030
5,982
Hypertension patients, 2030
+643 on today
67.6%
QRISK ≥20% on statins, 2030
+1.50pp over 3 yrs
4.4%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Respiratory annual review rates fell over three years.
COPD reviews fell 16.0% to 68.8% (England 76.4 percent) and asthma reviews fell 13.3% to 58.4% (about 810 unreviewed patients), which may reflect recall.
Core20 share and phone access vary across practices.
Core20 share spans 71.7 pp from Holes Lane Medical Ltd.
Breast, cervical screening and hypertension control beat England.
Breast screening reaches 78.2% (England 69.9 percent), cervical screening reaches 73.6% (England 66.8 percent), and hypertension treated to target is 71.6% (England 70.3 percent).
Population, age and ethnicity
Older patients comprise 20.1% of the list alongside 94.2% White resident ethnicity
Warrington Central East PCN has 27,823 registered patients, with 20.1% (5,589 patients) aged 65+, above Warrington (LAD) (17.5%), the ICB (19.0%) and England (17.9%). Projected population growth to 2030 is 0.1%, below Warrington (LAD) (0.7%), the ICB (2.3%) and England (2.3%), though projection methodology is unverified. Area Census resident data indicates 94.2% White ethnicity (Warrington (LAD) 93.5%, the ICB 93.0%, England 81.1%) and a 5.8% ethnic minority share, led by Asian or Asian British residents at 2.7% (Warrington (LAD) 3.3%, the ICB 2.8%, England 9.6%). These resident figures reflect catchment populations rather than registered patients.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Warrington (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Warrington LA) | 1,737 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.8% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 58.8% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Warrington LA) | 905 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Warrington LA) | 12.1 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Registered Core20 share is 22.8% overall yet spans 71.7 pp across practices
Registered Core20 share is 22.8% (Warrington (LAD) 16.9 percent, ICB 31.9 percent, England 21.0 percent), but practice shares span 71.7 pp, from 7.2% at Holes Lane Medical Ltd. to 78.9% at Cockhedge Medical Centre (2,217 estimated Core20 patients). Greenbank Surgery accounts for 2,003 estimated patients at 25.9% share. Practice estimates sum to 6,878, whereas associated-resident deciles 1 and 2 estimate 3,741. Reconciling resident and registered bases is essential before targeting outreach.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
275
SMI register
0.95% recorded prevalence
139
Learning disability register
0.48% recorded prevalence
7
Care homes, 329 beds
In the PCN catchment
9.4%
Provide unpaid care
Warrington (LAD), Census 2021
Learning disability prevalence is 0.5% (139 patients), against 0.5% in Warrington, 0.6% in the ICB and 0.6% in England. Severe mental illness prevalence is 0.9% (275 patients), trailing Warrington (1.0%), the ICB (1.1%) and England (1.0%). The PCN catchment includes 7 care homes with 329 beds.
Severe mental illness: physical health checks
Although SMI blood pressure checks reached 86.3% (England 83.4%), BMI recording fell 0.02 pp over 2023 to 2025 (England +5.1 pp). Greenbank Surgery recorded 76.3% for blood pressure, consistent with uneven physical health monitoring across practices.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
5,339
Hypertension register
+5.85%
Register growth, 3 yrs
Warrington (LAD) +6.41% · England +5.60%
+2.38pp
BP control, under 80
≤140/90 · −0.85pp aged 80+
+643
More patients by 2030
Forecast 5,982 (20.77%)
Hypertension case-finding and control
Recorded hypertension prevalence is 18.5% (5,339 patients), above Warrington (16.4%), the ICB (16.8%) and England (15.2%). While 71.6% of patients are treated to target (England 70.3%), recent blood pressure recording stands at 85.9%, trailing England (90.0%) and the ICB (88.3%). Furthermore, control in patients aged 80+ fell 0.8 pp (England +1.8 pp) over 2023 to 2025. Trailing recent monitoring and falling control in patients aged 80+ point to an opportunity to prioritise systematic blood pressure recall for older cohorts.
Lipids and statins
Patients with QRISK ≥ 20% on lipid-lowering therapy reached 64.5%, above England (63.6%) and Warrington (61.6%), though three-year growth was +2.4% (England +6.2%). CKD treatment stands at 73.3% (England 70.3%). Slower uptake growth than England highlights an opportunity to audit and expand recall for high-risk primary prevention patients.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 49,422 | £1.70 | £1.71 | £1.86 | £84,017 |
| Cardiovascular (all), 2025 | 69,511 | £5.48 | £4.37 | £3.33 | £380,920 |
In 2026, 49,422 lipid-modifying items were prescribed at £1.70 per item (Warrington £1.59, ICB £1.71, England £1.86), spending £7,908 less than at England's unit cost. Spending less per item than England reflects low unit drug expenditure, meaning clinical review and treatment reach should remain the priority.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
−13.32%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.28%
Asthma prevalence, PCN 3-yr % change
COPD prevalence is 2.2% (624 patients; England 1.9%), growing +10.2% over 2023 to 2025 (England +2.6%). However, annual COPD reviews fell 16.0% to 68.8% (England 76.4%, England change +2.8%). Similarly, asthma reviews fell 13.3% over 2023 to 2025 to 58.4% (England 65.7%, England change +4.4%), leaving an estimated scale of about 810 unreviewed patients across the 1,942 register. Paediatric asthma prescribing reached 1,840 items per 1,000 aged 5-19 (England 1,488). Falling review rates alongside growing registers could reflect recall capacity pressures, which an audit would test.
Cancer register and children's immunisation
Cancer prevalence is 3.9% (1,127 patients; England 3.8%), growing +6.0% over 2023 to 2025 (England +9.0%). In Q1 2025/26, childhood immunisations trail the 95.0% target: 6-in-1 coverage at 12 months is 88.7% (England 91.0%), MMR dose 2 at age 5 is 87.7% (England 82.8%), and 4-in-1 pre-school booster coverage is 81.5% (England 80.9%). Small quarterly cohorts limit causal conclusions, but pre-school booster shortfalls warrant targeted recall.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of staged cancers (7,482 of 13,490 with known stage) were diagnosed at stage 1 or 2, against 55.3% in England and 19.5 pp below the 75.0% national ambition. Known-stage share was 72.8% across 18,522 registered cancers. Early detection reached 87.1% in breast cancer but 44.9% in bowel cancer. PCN breast screening is 78.2% and cervical screening is 73.6%. Over 2023 to 2025, PCN cancer register growth was +6.0% (England +9.0%), whereas Cockhedge Medical Centre recorded -2.8%. Slower register growth could reflect non-screened presentation delays; a clinical audit would test this.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In July 2026, North Cheshire and Mersey NHS Foundation Trust achieved 83.7% on the 62-day cancer referral to treatment standard, below the 85.0% standard by 1.3 pp, but exceeding Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), Manchester University NHS Foundation Trust (72.8%), the ICB (76.2%) and England (71.2%). Its 28-day faster diagnosis reached 80.2% (standard 75.0%). Diagnostic 6-week waits were low for MRI (0.5%) and CT (2.3%), though echocardiography reached 28.0% (England 28.5%). These provider metrics describe acute system timeliness rather than PCN-specific patient pathways.
| Pathways within standard (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.21 | 72.39 | 80.06 | 77.25 | 79.32 |
| 31-day treatment (96%) | 98.17 | 95.46 | 92.54 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.67 | 77.96 | 72.85 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | England |
|---|---|---|---|---|
| MRI | 0.53 | 14.04 | 11.68 | 21.40 |
| CT | 2.32 | 13.08 | 14.66 | 9.92 |
| Echocardiography | 28.04 | 34.88 | 4.91 | 28.48 |
| Colonoscopy | 15.98 | 18.04 | 4.51 | 30.83 |
| Gastroscopy | 20.24 | 18.17 | 29.35 | 29.02 |
| All 15 DM01 tests | 6.34 | 21.17 | 8.98 | 23.14 |
| Community services activity | Warrington residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 38,550 | 541,280 |
| Referrals | 7,320 | 97,150 |
| Patients with a contact | 14,830 | 146,240 |
Community services (residents of Warrington), Jun 2026 (provisional). In June 2026, adults aged 65+ accounted for 56% of community service contacts among Warrington borough residents (21,595 of 38,550 total contacts). This activity captures borough-wide resident contacts rather than PCN-registered activity, highlighting substantial community operational demand concentrated in older age groups across the local system.
Practice variation and patient experience
Practice phone access spans 41.8 pp while vaccination achievement ranges by 62.9 pp
For 2025/26, the range in QOF vaccination and immunisation-domain achievement from Manchester Road Surgery to Holes Lane Medical Ltd. was 62.9 pp. Achievement was 37.1% at Manchester Road Surgery, while achievement was 100.0% at Holes Lane Medical Ltd.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Manchester Road | 93 | 25.4 | 75.5% | 58.0% | 86.2% |
| Holes Lane | 114 | 7.2 | 68.5% | 61.1% | 81.0% |
| Cockhedge | 81 | 78.9 | 89.6% | 77.2% | 80.9% |
| Fairfield Surgery | 106 | 26.7 | 75.2% | 68.5% | 77.1% |
| Greenbank Surgery | 112 | 25.9 | 47.8% | 70.3% | 63.6% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
COPD and heart failure annual reviews fell over three years while England rose
Across 25 compared measures, 14 trail England's three-year trend. The widest relative declines occurred in annual reviews over 2023 to 2025: COPD fell 16.0% (England +2.8%), heart failure fell 9.0% (England +8.7%), and asthma fell 13.3% (England +4.4%). In percentage points, alcohol recording in psychosis fell 7.8 pp (England +5.4 pp). Conversely, strengths include statin therapy for diabetes without cardiovascular disease, which rose +4.8% (England +2.1%), and cervical screening, which rose +1.1% (England -1.0%). These divergent paths could reflect condition-specific recall capacity pressures; a recall-list audit would test this.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
COPD reviews
Heart failure reviews
Asthma reviews
Alcohol record (psychosis)
BMI record (SMI)
Diabetes statin (no CVD)
Cervical screening
Diabetes statin (CVD)
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Warrington (LAD) | Asset | PCN | Warrington (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 7 (329 beds) | n/a | Schools (catchment) | 45 | n/a |
| Children's centres | 4 | 12 | Places of worship | 22 | 89 |
| Libraries | 1 | 7 | Primary schools (LA maintained) | 7 | 28 |
| Primary academies | 7 | 31 | Special schools | 1 | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Structured asthma and COPD review recall
Asthma reviews are 58.4% (England 65.7%; register 1,942, about 810 unreviewed) after falling 13.3% over 2023 to 2025; COPD reviews fell 16.0% to 68.8% (England 76.4%; register 624). For discussion: run a respiratory recall audit, offering flexible review slots and pairing inhaler checks with high-Core20 practice lists. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 2
Two-list Core20 and telephony access review
Practice Core20 share spans 71.7 pp (7.2% at Holes Lane Medical Ltd. to 78.9% at Cockhedge Medical Centre); phone access spans 41.8 pp (47.8% at Greenbank Surgery to 89.6% at Cockhedge Medical Centre). Low cost, quick to run.
Evidence base: the share of patients in the most deprived quintile is the Core20 targeting measure used to weight inequalities funding, outreach and prevention capacity, and the gradient every clinical indicator should be read against.
Policy anchor: Core20PLUS5 (Core20 = the most deprived 20% by IMD); 10 Year Health Plan, with widening inequalities the equity test of reform.
Option 3
Older adult cardiovascular and frailty recall
Recent BP recording is 85.9% (England 90.0%; PCN register 5,339), 80+ BP control fell 0.8 pp (England +1.8 pp), heart failure reviews fell 9.0% to 78.7%, and frail diabetes HbA1c control is 79.8% (England 81.9%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Older adult frailty capacity review (p2) | Aged 65+ | Neighbourhood health framework · NHS vaccination strategy | PCN |
| Reconciled Core20 targeting audit (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health recall audit (p4) | SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | Practice |
| Hypertension recall audit (p5) | Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school booster recall audit (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cancer referral and presentation audit (p7) | Cancer: QOF prevalence | Core20PLUS5, 75% stage 1–2 by 2028 | PCN |
| Practice telephony and triage review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Structured asthma and COPD review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) · COPD register | Core20PLUS5 respiratory | PCN |
| Option 2 · Two-list Core20 and telephony access review (p12) | Core20 cohort (IMD quintile 1) · GPPS easy to contact the practice by phone | Core20PLUS5 · 10YHP equity test · 10YHP, hospital to community | PCN & Practice |
| Option 3 · Older adult cardiovascular and frailty recall (p12) | Hypertension register · Hypertension patients with a recent BP reading · Last BP reading of patients (80+ yrs with hypertension) in the last 12 months is <= 150/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
